Biocon, a leading biopharmaceutical company, successfully raised Rs 4,500 crore through QIP. This marks their first equity funding since 2004. The QIP saw strong interest from domestic and international investors. The raised capital will be used to purchase debentures and repay borrowings. Kotak Mahindra Capital, BofA India Securities, and Goldman Sachs (India) Securities managed the QIP.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets